News und Analysen
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now
Investors looking to pad their passive income streams with high-yield dividend stocks have three excellent choices. If you have an extra $100 to invest, you could set yourself up with dividends from
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight
Is Novavax Stock a Buy?
Novavax (NASDAQ: NVAX) has been a highly volatile stock in recent years, and that volatility is on full display again this month. Shares of the healthcare stock are up 200% since the start of May
EQS-News: STRATEC ANNUAL GENERAL MEETING ADOPTS RESOLUTION ON DIVIDEND AND APPROVES ALL AGENDA ITEMS
Is CRISPR Therapeutics Stock a Buy?
CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for
Is CRISPR Therapeutics Stock a Buy?
CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for
Is CRISPR Therapeutics Stock a Buy?
CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for
Is Viking Therapeutics Stock a Buy?
Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster --
2 Top Growth Stocks Down 24% and 50% to Buy With $100
The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You
2 Top Growth Stocks Down 24% and 50% to Buy With $100
The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You
If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
If you'd invested $10,000 in Novavax (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant
These Dividend Stocks Are an Investor's Best Friend
Dividend stocks tend to struggle in high-interest-rate environments. The core reason is investors have an abundance of low-risk, high-yield income options when interest rates spike.
Conversely, fund
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.
Eli Lilly (NYSE: LLY) and Regeneron
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.
Eli Lilly (NYSE: LLY) and Regeneron
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.
Eli Lilly (NYSE: LLY) and Regeneron
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ
QuidelOrtho Corporation (Nasdaq: QDEL) has launched a second state-of-the-art United States distribution center in Pedricktown, New Jersey. This strategic endeavor epitomizes QuidelOrtho’s
1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?
Novavax (NASDAQ: NVAX) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with
Humana Ranks 6th Overall in Fair360 National Companies for Diversity
Humana Inc. (NYSE: HUM) has ascended to No. 6 on Fair360’s prestigious list of the Top 50 Companies for Workplace Fairness, marking its seventh consecutive year in the top rankings. This
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this
Novavax Stock Just Tripled. Is It Too Late to Buy?
After losing more than 90% of its value from a peak back in 2021, Novavax (NASDAQ: NVAX) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon